CORRECTION: Stemline Therapeutics Sees Q4 Sees Prelim. Q4 Net Revenues For ELZONRIS $11.8M; A Prior Headline Indicated This Was The FY19 Estimate, This Was Incorrect

Benzinga · 01/13/2020 21:26